We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > EDIT-101

News List

FDA clears clinical testing of Editas Medicine's gene-editing drug EDIT-101 firstwordpharma
December 03, 2018
Editas Medicine on Friday announced that the FDA has approved the launch of a Phase I/II trial for EDIT-101, an experimental CRISPR genome-editing drug being developed to treat Leber's congenital amaurosis type 10 (LCA10). According to Editas, EDIT-101 is
FDA clears clinical testing of Editas Medicine's gene-editing drug EDIT-101 firstwordpharma
December 03, 2018
Editas Medicine on Friday announced that the FDA has approved the launch of a Phase I/II trial for EDIT-101, an experimental CRISPR genome-editing drug being developed to treat Leber's congenital amaurosis type 10 (LCA10). According to Editas, EDIT-101 is
Allergan, Editas Medicine to Jointly Develop EDIT-101 americanpharmaceuticalreview
August 08, 2018
Allergan and Editas Medicine announced Allergan's wholly-owned subsidiary, Allergan Pharmaceuticals International Limited (Allergan), has exercised its option to develop and commercialize EDIT-101 globally for the treatment of LCA10.....